AR039231A1 - Agentes de union ox40r novedosos - Google Patents
Agentes de union ox40r novedososInfo
- Publication number
- AR039231A1 AR039231A1 ARP030101155A ARP030101155A AR039231A1 AR 039231 A1 AR039231 A1 AR 039231A1 AR P030101155 A ARP030101155 A AR P030101155A AR P030101155 A ARP030101155 A AR P030101155A AR 039231 A1 AR039231 A1 AR 039231A1
- Authority
- AR
- Argentina
- Prior art keywords
- ox40r
- ox40l
- peptides
- new
- binding
- Prior art date
Links
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 abstract 5
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000004473 OX40 Ligand Human genes 0.000 abstract 3
- 108010042215 OX40 Ligand Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 239000011230 binding agent Substances 0.000 abstract 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000051450 human TNFSF4 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente revela los péptidos aislados del dominio extracelular del Ligando OX40 (OX40L) capaz de unir al Receptor OX40 (OX40R) e inhibir la interacción de OX40R-OX40L. Tales péptidos, las proteínas de fusión que los comprenden, tanto como los péptidos y otras moléculas disenadas en sus secuencias, pueden ser utilizados como agentes de unión OX40R que compiten con un OX40L natural para bloquear la senalización activada OX40R en la profilaxis y/o el tratamiento de las enfermedades relacionadas con las células T. Reivindicación 1: Un agente de unión OX40R que es la secuencia de péptido correspondiente a los aminoácidos 94-124 (SEC. ID NO: 6) del OX40L humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02100334 | 2002-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039231A1 true AR039231A1 (es) | 2005-02-09 |
Family
ID=28459562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101155A AR039231A1 (es) | 2002-04-03 | 2003-04-02 | Agentes de union ox40r novedosos |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7758852B2 (es) |
| EP (1) | EP1492813B1 (es) |
| JP (1) | JP4426315B2 (es) |
| AR (1) | AR039231A1 (es) |
| AT (1) | ATE557036T1 (es) |
| AU (1) | AU2003240761B2 (es) |
| CA (1) | CA2480694A1 (es) |
| ES (1) | ES2387767T3 (es) |
| IL (1) | IL164376A0 (es) |
| WO (1) | WO2003082919A2 (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004281817B2 (en) | 2003-10-17 | 2010-07-22 | Baylor College Of Medicine | A method for increasing CD8+ cytotoxic T cell reponses and for treating multiple sclerosis |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| JP2009519718A (ja) | 2005-12-16 | 2009-05-21 | ジェネンテック・インコーポレーテッド | 抗ｏｘ４０ｌ抗体とその使用方法 |
| US20110008368A1 (en) * | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
| CA2656923A1 (en) * | 2006-06-21 | 2007-12-27 | Genentech, Inc. | Crystal structures of ox40l and ox40l complexed with ox40 receptor |
| US9347947B2 (en) * | 2009-03-12 | 2016-05-24 | Siemens Healthcare Diagnostics Inc. | Immunoassays employing non-particulate chemiluminescent reagent |
| CN106554417B (zh) | 2010-08-23 | 2020-11-06 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
| RU2562874C1 (ru) * | 2011-08-23 | 2015-09-10 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела против ох40 и способы их применения |
| JP2015516143A (ja) * | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
| US10696946B2 (en) | 2013-02-22 | 2020-06-30 | The Board Of Trustees Of The University Of Illinois | T-REG cell expansion |
| US20140294792A1 (en) * | 2013-02-22 | 2014-10-02 | The Board Of Trustees Of The University Of Illinois | T-REG Cell Expansion |
| JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトｏｘ４０リガンド抗体、及びこれを含む抗インフルエンザ薬 |
| CN106999577B (zh) | 2014-07-16 | 2021-12-21 | 特兰斯吉恩股份有限公司 | 溶瘤病毒和免疫检查点调节因子组合 |
| JP6895374B2 (ja) | 2014-07-16 | 2021-06-30 | トランジェーヌＴｒａｎｓｇｅｎｅ | 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| SG11201705844SA (en) * | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
| WO2016128542A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| EP3331919A1 (en) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| CA3006934A1 (en) | 2015-12-01 | 2017-06-08 | Glaxosmithkline Intellectual Property Development Limited | Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof |
| HK1250032A1 (zh) | 2015-12-03 | 2018-11-23 | Glaxosmithkline Intellectual Property Development Limited | 作为sting调节剂的环状嘌呤二核苷酸 |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| US10975287B2 (en) | 2016-04-07 | 2021-04-13 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| AU2017247798C1 (en) | 2016-04-07 | 2020-08-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| AU2017260854B2 (en) | 2016-05-05 | 2020-01-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of Zeste Homolog 2 inhibitors |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| EP3494140A1 (en) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos and anti-pd-1 antibody combination therapy |
| US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
| CA3045241A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| CN110234342A (zh) | 2016-12-01 | 2019-09-13 | 葛兰素史密斯克莱知识产权发展有限公司 | 组合疗法 |
| WO2018157163A1 (en) * | 2017-02-27 | 2018-08-30 | Shattuck Labs, Inc. | Vsig8-based chimeric proteins |
| EP3585782A1 (en) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| BR112019025257A2 (pt) | 2017-06-09 | 2020-09-29 | Glaxosmithkline Intellectual Property Development Limited | método para tratar câncer, e, anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo |
| CA3066007A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| US20210238172A1 (en) | 2017-10-05 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators and methods of using the same |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN113795512A (zh) | 2019-02-01 | 2021-12-14 | 葛兰素史克知识产权开发有限公司 | 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法 |
| CN114222760A (zh) | 2019-06-26 | 2022-03-22 | 葛兰素史密斯克莱知识产权发展有限公司 | Il1rap结合蛋白 |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| CA3155173A1 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| AU2020409429A1 (en) | 2019-12-18 | 2022-06-16 | Ctxt Pty Ltd | Compounds |
| CN115038466A (zh) | 2020-01-28 | 2022-09-09 | 葛兰素史密斯克莱知识产权发展有限公司 | 联合治疗及其用途和方法 |
| CN113754778A (zh) * | 2020-06-05 | 2021-12-07 | 上海交通大学 | 靶向cldn18.2的嵌合抗原受体及其用途 |
| AU2022230795B2 (en) | 2021-03-02 | 2025-02-13 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| EP4314060A1 (en) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106197A (en) * | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6602856B1 (en) * | 1995-01-17 | 2003-08-05 | J. Mark Quillan | Antagonists of alpha-melanocyte stimulating hormone and methods based thereon |
| US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EP1171626A4 (en) * | 1999-03-26 | 2002-10-30 | Human Genome Sciences Inc | FIFTY HUMAN SECRETED PROTEINS |
| US6872519B1 (en) * | 1999-04-27 | 2005-03-29 | Mirus Bio Corporation | In vitro process for selecting phage resistant to blood inactivation |
| GB2373500B (en) * | 2000-02-04 | 2004-12-15 | Aeomica Inc | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| WO2001072771A2 (en) | 2000-03-29 | 2001-10-04 | Dgi Biotechnologies, L.L.C. | Insulin and igf-1 receptor agonists and antagonists |
-
2002
- 2002-04-03 IL IL16437602A patent/IL164376A0/xx unknown
-
2003
- 2003-04-02 JP JP2003580382A patent/JP4426315B2/ja not_active Expired - Fee Related
- 2003-04-02 AR ARP030101155A patent/AR039231A1/es not_active Application Discontinuation
- 2003-04-02 CA CA002480694A patent/CA2480694A1/en not_active Abandoned
- 2003-04-02 WO PCT/EP2003/050089 patent/WO2003082919A2/en not_active Ceased
- 2003-04-02 ES ES03730172T patent/ES2387767T3/es not_active Expired - Lifetime
- 2003-04-02 AT AT03730172T patent/ATE557036T1/de active
- 2003-04-02 EP EP03730172A patent/EP1492813B1/en not_active Expired - Lifetime
- 2003-04-02 AU AU2003240761A patent/AU2003240761B2/en not_active Ceased
- 2003-04-02 US US10/510,015 patent/US7758852B2/en not_active Expired - Fee Related
-
2009
- 2009-11-24 US US12/624,534 patent/US7858765B2/en not_active Expired - Fee Related
-
2010
- 2010-11-23 US US12/952,226 patent/US20110086057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003240761B2 (en) | 2009-04-23 |
| US7758852B2 (en) | 2010-07-20 |
| EP1492813A2 (en) | 2005-01-05 |
| US7858765B2 (en) | 2010-12-28 |
| EP1492813B1 (en) | 2012-05-09 |
| WO2003082919A2 (en) | 2003-10-09 |
| AU2003240761A1 (en) | 2003-10-13 |
| WO2003082919A3 (en) | 2004-02-05 |
| US20070009964A1 (en) | 2007-01-11 |
| ES2387767T3 (es) | 2012-10-01 |
| IL164376A0 (en) | 2005-12-18 |
| ATE557036T1 (de) | 2012-05-15 |
| JP4426315B2 (ja) | 2010-03-03 |
| JP2006506041A (ja) | 2006-02-23 |
| US20100136628A1 (en) | 2010-06-03 |
| US20110086057A1 (en) | 2011-04-14 |
| CA2480694A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039231A1 (es) | Agentes de union ox40r novedosos | |
| NL300013I1 (nl) | Nieuwe protein met TNF-remmende werking en hun ber | |
| Bazaa et al. | MVL-PLA2, a phospholipase A2 from Macrovipera lebetina transmediterranea venom, inhibits tumor cells adhesion and migration | |
| AR072009A1 (es) | Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos | |
| NZ593815A (en) | Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| ATE338121T1 (de) | Von muc-1 abgeleitete peptide | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| NO20001600D0 (no) | Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| ES2160485B1 (es) | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. | |
| RU2010110564A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| DE69638023D1 (de) | Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden | |
| NO20001599D0 (no) | Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser | |
| DE69638022D1 (de) | Aus wirbeltieren und darauf basierende verfahren | |
| ATE106449T1 (de) | Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen. | |
| MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
| ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| Blishchenko et al. | Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin β-chain | |
| BRPI0506148A (pt) | preparação farmacêutica para o tratamento de choque | |
| AR024472A1 (es) | Inhibidores de la integrina alfav beta6. | |
| ATE367438T1 (de) | Verfahren zur steigerung der expression von menschlichen tnf-rezeptor | |
| NO20034146D0 (no) | Syntetiske peptider og fremgangsmåte for forebyggende og terapeutisk anvendelse i kreftinvasjon og metastase | |
| EA200100314A1 (ru) | Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины | |
| DE60120507D1 (de) | Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |